Circulating progenitor cells and scleroderma

Current Rheumatology Reports

Volumn 10, Issue 3, 2008, Pages 183-188

  Gomer, Richard H ^a  

^a RICE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOSTATIN; ATORVASTATIN; CD133 ANTIGEN; CD14 ANTIGEN; CD45 ANTIGEN; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SERUM AMYLOID P; STROMAL CELL DERIVED FACTOR 1; THYMOCYTE ANTIBODY; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; IMMUNOSUPPRESSIVE AGENT;

ANGIOGENESIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; CD34 SELECTION; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; DIFFUSE SCLERODERMA; DRUG MEGADOSE; ENDOTHELIUM CELL; FIBROBLAST; FIBROSIS; HEART MUSCLE FIBROSIS; HUMAN; ISCHEMIA; LUNG FIBROSIS; MONOTHERAPY; NONHUMAN; REVIEW; SCLERODERMA; STEM CELL; HEMATOPOIETIC STEM CELL; PATHOPHYSIOLOGY; PHYSIOLOGY; STEM CELL TRANSPLANTATION; SYSTEMIC SCLEROSIS; VASCULAR ENDOTHELIUM;

CYCLOPHOSPHAMIDE; ENDOTHELIUM, VASCULAR; FIBROBLASTS; HEMATOPOIETIC STEM CELLS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; SCLERODERMA, SYSTEMIC; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 51449117441     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-008-0031-8     Document Type: Review

References (50)

1. Abraham DJ, Varga J: Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 2005, 26:587-595.
2. Zhou X, Tan FK, Wang N, et al.: Genome-wide association study for regions of systemic sclerosis susceptibility in a Choctaw Indian population with high disease prevalence. Arthritis Rheum 2003, 48:2585.
3. Bucala R, Spiegel L, Chesney J, et al.: Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med 1994, 1:71-81.
4. Zhao Y, Glesne D, Huberman E: A human peripheral blood monocyte-derived subset acts as pluripotent stem cells. Proc Natl Acad Sci U S A 2003, 100:2426-2431.
5. Hinchcliff M, Varga J: Novel paradigm for treating vasculopathy in systemic sclerosis: vascular progenitor cells and statins. Curr Rheumatol Rep 2007, 9:1-3.
6. Hristov M, Weber C: Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance. J Cell Mol Med 2004, 8:498-508.
7. Takahashi T, Kalka C, Masuda H, et al.: Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999, 5:434-438.
8. Smadja DM, Cornet A, Emmerich J, et al.: Endothelial progenitor cells: characterization, in vitro expansion, and prospects for autologous cell therapy. Cell Biol Toxicol 2007, 23:223-239.
9. Asahara T, Murohara T, Sullivan A, et al.: Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275:964-967.
10. Crosby JR, Kaminski WE, Schatteman G, et al.: Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Circ Res 2000, 87:728-730.
11. Murasawa S, Asahara T: Endothelial progenitor cells for vasculogenesis. Physiology (Bethesda) 2005, 20:36-42.
12. Kuwana M, Okazaki Y, Yasuoka H, et al.: Defective vasculogenesis in systemic sclerosis. Lancet 2004, 364:603-610.
13. Del Papa N, Quirici N, Soligo D, et al.: Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum 2006, 54:2605-2615.
14. Allanore Y, Batteux F, Avouac J, et al.: Levels of circulating endothelial progenitor cells in systemic sclerosis. Clin Exp Rheumatol 2007, 25:60-66.
15. Distler O, Del Rosso A, Giacomelli R, et al.: Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 2002, 4:R11.
16. Mulligan-Kehoe MJ, Drinane MC, Mollmark J, et al.: Antiangiogenic plasma activity in patients with systemic sclerosis. Arthritis Rheum 2007, 56:3448-3458.
17. Ito H, Rovira, II, Bloom ML, et al.: Endothelial progenitor cells as putative targets for angiostatin. Cancer Res 1999, 59:5875-5877.
18. Cipriani P, Guiducci S, Miniati I, et al.: Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. Arthritis Rheum 2007, 56:1994-2004.
19. Deshane J, Chen S, Caballero S, et al.: Stromal cell-derived factor 1 promotes angiogenesis via a heme oxygenase 1-dependent mechanism. J Exp Med 2007, 204:605-618.
20. Tourkina E, Gooz P, Oates JC, et al.: Curcumin-induced apoptosis in scleroderma lung fibroblasts: role of protein kinase cepsilon. Am J Respir Cell Mol Biol 2004, 31:28-35.
21. Schmidt M, Sun G, Stacey M, et al.: Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma. J Immunol 2003, 171:380-389.
22. Wang J, Jiao H, Stewart TL, et al.: Improvement in postburn hypertrophic scar after treatment with IFN-alpha2b is associated with decreased fibrocytes. J Interferon Cytokine Res 2007, 27:921-930.
23. Bellini A, Mattoli S: The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab Invest 2007, 87:858-870.
24. Hur J, Yoon CH, Kim HS, et al.: Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol 2004, 24:288-293.
25. Haudek SB, Xia Y, Huebener P, et al.: Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice. Proc Natl Acad Sci U S A 2006, 103:18284-18289.
26. Kraling BM, Maul GG, Jimenez SA: Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. Pathobiology 1995, 63:48.
27. Abraham D, Distler O: How does endothelial cell injury start? The role of endothelin in systemic sclerosis. Arthritis Res Ther 2007, 9(Suppl 2):S2.
28. Chesney J, Metz C, Stavitsky AB, et al.: Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes. J Immunol 1998, 160:419-425.
29. Hartlapp I, Abe R, Saeed RW, et al.: Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo. FASEB J 2001, 15:2215.
30. Wang JF, Jiao H, Stewart TL, et al.: Fibrocytes from burn patients regulate the activities of fibroblasts. Wound Repair Regen 2007, 15:113-21.
31. Postlethwaite AE, Shigemitsu H, Kanangat S: Cellular origins of fibroblasts: possible implications for organ fibrosis in systemic sclerosis. Curr Opin Rheumatol 2004, 16:733-738.
32. Russo R, Medbury H, Guiffre A, et al.: Lack of increased expression of cell surface markers for circulating fibrocyte progenitors in limited scleroderma. Clin Rheumatol 2007, 26:1136-1141.
33. Mehrad B, Burdick MD, Zisman DA, et al.: Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease. Biochem Biophys Res Commun 2007, 353:104-108.
34. Aiba S, Tabata N, Ohtani H, et al.: CD34+ spindle-shaped cells selectively disappear from the skin lesion of scleroderma. Arch Dermatol 1994, 130:593-597.
35. Cowper SE: Nephrogenic systemic fibrosis: a review and exploration of the role of gadolinium. Adv Dermatol 2007, 23:131-154.
36. Vasa M, Fichtlscherer S, Adler K, et al.: Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001, 103:2885-2890.
37. Llevadot J, Murasawa S, Kureishi Y, et al.: HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 2001, 108:399-405.
38. Kuwana M, Kaburaki J, Okazaki Y, et al.: Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis. Arthritis Rheum 2006, 54:1946-1951.
39. Hristov M, Fach C, Becker C, et al.: Reduced numbers of circulating endothelial progenitor cells in patients with coronary artery disease associated with long-term statin treatment. Atherosclerosis 2007, 192:413-420.
40. Dazzi F, van Laar JM, Cope A, et al.: Cell therapy for autoimmune diseases. Arthritis Res Ther 2007, 9:206.
41. van Laar JM, Tyndall A: Adult stem cells in the treatment of autoimmune diseases. Rheumatology (Oxford) 2006, 45:1187-1193.
42. Tyndall A, Furst DE: Adult stem cell treatment of scleroderma. Curr Opin Rheumatol 2007, 19:604-610.
43. Ravagnani F, Siena S, Bregni M, et al.: Methodologies to estimate circulating hematopoietic progenitors for autologous transplantation in cancer patients. Haematologica 1991, 76(Suppl 1):46-49.
44. Murasawa S, Asahara T: Gene modified cell transplantation for vascular regeneration. Curr Gene Ther 2007, 7:1-6.
45. Gordon MY, Goldman JM, Gordon-Smith EC: 4-Hydroperoxycyclophosphamide inhibits proliferation by human granulocyte-macrophage colony-forming cells (GM-CFC) but spares more primitive progenitor cells. Leuk Res 1985, 9:1017-1021.
46. Brodsky RA, Sensenbrenner LL, Smith BD, et al.: Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia. Ann Intern Med 2001, 135:477-483.
47. Tehlirian CV, Hummers LK, White B, et al.: High dose cyclophosphamide without stem cell rescue in scleroderma. Ann Rheum Dis 2007 (Epub ahead of print).
48. Pilling D, Buckley CD, Salmon M, et al.: Inhibition of fibrocyte differentiation by serum amyloid P. J Immunol 2003, 17:5537-5546.
49. Tennent GA, Dziadzio M, Triantafillidou E, et al.: Normal circulating serum amyloid P component concentration in systemic sclerosis. Arthritis Rheum 2007, 56:2013-2017.
50. Pilling D, Roife D, Wang M, et al.: Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P. J Immunol 2007, 179:4035-4044.